2 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
Follow Relapse Multiple Myeloma: new trials by email Literature Review of Relapse Multiple Myeloma trials Research Report on Relapse Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma Pomalidomide, Dexamethasone, INCB053914 50 mg bis in die (BID) - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Withdrawn | Medical College of Wisconsin | 2021-07-01 | 2020-08-19 | |
| A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma OPD5 - Relapse Multiple Myeloma, Multiple Myeloma | Phase 1 | Withdrawn | Oncopeptides AB | 2021-05-27 | 2021-11-26 |
Multiple Myeloma (2)
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Vascular Diseases (2)
BID protein, human (1) · Calcium Dobesilate (1) · Dexamethasone (1) · pomalidomide (1)
Medical College of Wisconsin (1) · Oncopeptides AB (1)
Czechia (1)
Binod Dhakal, MD (1) · Sergio Giralt, MD (1)